Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The present study is intended to investigate the objective response rate (ORR) and the
progression-free survival (PFS) of the patients with histologically- or
cytologically-confirmed metastatic pancreatic cancer after treating with the combination of
camrelizumab, gemcitabine and nab-paclitaxel, and to investigate the overall survival (OS)
and the adverse event (AE) of the patients with histologically- or cytologically-confirmed
metastatic pancreatic cancer after treating with the combination of camrelizumab, gemcitabine
and nab-paclitaxel.